Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Frans J. Cleton"'
Autor:
Marcel P. M. Stokkel, Emilio Bombardieri, Ernest K. J. Pauwels, E. J. C. Sturm, Frans J. Cleton
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 126:549-559
Over the past decades, Positron Emission Tomography has opened a new field of imaging. Nowadays, this technique is being used for diagnosing, staging disease as well as for prognostic stratification and monitoring therapy. In this respect, [18F]fluor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db10b3a2b9a44fc47499bfc66f7b3ee9
https://doi.org/10.1007/pl00008465
https://doi.org/10.1007/pl00008465
Autor:
Marianne A. Nooy, Marc F. J. Rutten, N.I. Weijl, Aeilko H. Zwinderman, Susanne Osanto, H. Jan Keizer, Frits R. Rosendaal, Frans J. Cleton
Publikováno v:
Journal of Clinical Oncology. 18:2169-2178
PURPOSE: To evaluate the risk of major thromboembolic complications in male germ cell cancer patients receiving cisplatin-based chemotherapy and to review the literature on this subject. PATIENTS AND METHODS: One hundred seventy-nine germ cell cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68d6b6131b9cd767dbc210454be0df86
https://doi.org/10.1200/jco.2000.18.10.2169
https://doi.org/10.1200/jco.2000.18.10.2169
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 122:513-532
Somatostatin receptor scintigraphy (SRS) with the diethylenetriaminopentaacetic-acid-conjugated somatostatin analogue [111In-DTPA-D-Phe1] octreotide, also known as 111In-pentetreotide, is a new non-invasive modality for the evaluation of tumours that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86f681ccdd8f0d6b8bb35cc10296c379
https://doi.org/10.1007/bf01213548
https://doi.org/10.1007/bf01213548
Autor:
Mariëlle Nobbenhuis, Frans J. Cleton
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 118:395-399
Febrile neutropenic events (FNE) were studied in 90 patients on chemotherapy protocols for solid tumours, from 1986 to 1990. All patients received intensive chemotherapy with a high dose intensity. There were 51 FNE admissions in 31 patients, with an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c67cad7b9e0610bfc67b03512de92807
https://doi.org/10.1007/bf01294447
https://doi.org/10.1007/bf01294447
Publikováno v:
Gynecologic Oncology. 33:368-371
Eighteen patients with locoregional recurrence after primary surgery for carcinoma of the cervix and treated by radiotherapy were analyzed. An overall complete response of 88%, 16 of 18, was achieved. Five of sixteen patients (31%) developed a second
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b94733d4f861db51b312ffd11cd9e0e
https://doi.org/10.1016/0090-8258(89)90529-5
https://doi.org/10.1016/0090-8258(89)90529-5
Autor:
Albert M. I. H. Naipal, Susanne Osanto, Aad Van Leeuwen, Jan-Willem Gratama, Frans J. Cleton, Rumo Jansen
Publikováno v:
International Journal of Cancer. 43:1001-1006
The toxicity and therapeutic efficacy of the combination of recombinant interferon gamma (rIFN-gamma) and alpha (rIFN-alpha) was investigated in 15 patients with metastatic melanoma. Patients were treated with an escalating dose of rIFN-gamma and a f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43c4ec7682188a57636cf80703662d3e
https://doi.org/10.1002/ijc.2910430608
https://doi.org/10.1002/ijc.2910430608
Autor:
Kees Schaapveld, Frans J. Cleton
Publikováno v:
European Journal of Cancer and Clinical Oncology. 25:767-771
Future scenarios on cancer in The Netherlands were made with the help of existing trends, demographic changes and expected developments in cancer research, prevention, screening and treatment. Until the year 2000, cancer incidence will probably incre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af64eebfe555f91b10fab4e45d25c189
https://doi.org/10.1016/0277-5379(89)90219-8
https://doi.org/10.1016/0277-5379(89)90219-8